Loading cancer entity…
Loading cancer entity…
Clinical trials
24 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03728361 | Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | completed | Phase 2 | 55 | Dwight OwenOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06049966 | Atezolizumab in Large Cell Neuroendocrine Carcinoma(LANCE) | completed | Phase 1 | 22 | Oncology Center of Biochemical Education And ResearchOTHER | 1 | Jul 8, 2026 |
| NCT04010357 | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04452292 | Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma(PRECISION-NEC) | completed | N/A | 2 | Charles KunosOTHER | 1 | May 17, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials